Artemisinins in malaria treatment in the UK

Drug and Therapeutics Bulletin

Volumn 48, Issue 11, 2010, Pages 129-132

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIA ANNUA EXTRACT; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; CLINDAMYCIN; DIHYDROARTEMISININ; DOXYCYCLINE; FOLIC ACID ANTAGONIST; MEFLOQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

ANTIMALARIAL DRUG RESISTANCE; ARTEMISIA ANNUA; ARTHRALGIA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; FATIGUE; FEVER; GOOD MANUFACTURING PRACTICE; HEADACHE; HUMAN; HYPOGLYCEMIA; LICENSING; LOADING DRUG DOSE; MALARIA; MALARIA FALCIPARUM; MONOTHERAPY; MORTALITY; MYALGIA; NAUSEA; PARASITE; PATIENT COMPLIANCE; PLASMODIUM; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURVIVAL RATE; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM; VOMITING; DRUG COMBINATION;

ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; HUMANS; LICENSURE; MALARIA;

EID: 79952653007     PISSN: 00126543     EISSN: 17555248     Source Type: Journal    
DOI: 10.1136/dtb.2010.11.0057     Document Type: Review

References (36)

1. World Health Organization, 2010. Guidelines for the treatment of malaria: 2nd edition [online]. Available: http://whqlibdoc.who.int/publications/2010/ 9789241547925-eng.pdf [Accessed 21 October 2010].
2. Health Protection Agency, 2010. Malaria [online]. Available: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Malaria/ [Accessed 21 October 2010].
3. Olliaro PL, Taylor WR. Antimalarial compounds: from bench to bedside. J Exp Biol 2003; 206: 3753-9. (Pubitemid 37365457)
4. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113: 1084-92. (Pubitemid 38544090)
5. Qinghaosu Antimalaria Coordinating Research Group. Antimalaria studies on Qinghaosu. Chin Med J (Engl) 1979; 92: 811-6.
6. Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its dervatives. Crit Rev Toxicol 2010; 40: 405-21.
7. Riamet 20/120mg tablets. Summary of product characteristics, UK. Novartis, February 2010.
8. Joint Formulary Committee. British National Formulary. Edition 60. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, September 2010.
9. Anstey NM et al. Improving the availability of artesunate for treatment of severe malaria. Med J Aust 2006; 184: 3-4. (Pubitemid 43149788)
10. Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med 2008; 358: 1829-36.
11. Lalloo DG et al. UK malaria treatment guidelines. J Infect 2007; 54: 111-21. (Pubitemid 46083312)
12. World Health Organization, 2006. Guidelines for the treatment of malaria [online]. Available: http://whqlibdoc.who.int/publications/2006/9241546948-eng. pdf [Accessed 21 October 2010].
13. Moszynski P. Cambodia closes illegal pharmacies to protect malaria drugs. BMJ 2010; 340: 1107.
14. Maude RJ et al. Artemisinin antimalarials: preserving the "magic bullet". Drug Devel Res 2010; 71: 12-9.
15. Xiuquing J et al. Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria. Southeast Asian J Trop Med Public Health 1997; 28: 476-81.
16. Li G-Q et al. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg 1994; 88 (suppl 1): S5-6.
17. Giao PT et al. Artemisinin for treatment of uncomplicated falciparum malaria: is there a place for monotherapy? Am J Trop Med Hyg 2001; 65: 690-5.
18. Kappe SHI et al. That was then but this is now: malaria research in the time of an eradication agenda. Science 2010; 328: 862-6.
19. Udomsangpetch R et al. Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis 1996; 173: 691-8. (Pubitemid 26064072)
20. Luxemburger C et al. Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1994; 88: 213-7.
21. Nosten F et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994; 170: 971-7.
22. Nosten F et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356: 297-302. (Pubitemid 30459588)
23. Jansen FH et al. Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. Am J Trop Med Hyg 2007; 77: 1005-9.
24. Hatz C et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in non-immune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg 2008; 78: 241-7. (Pubitemid 351844558)
25. Medicines and Healthcare products Regulatory Agency, 2010. Good Manufacturing Practice [online]. Available: http://www.mhra.gov.uk/ Howweregulate/Medicines/Inspectionandstandards/GoodManufacturingPractice/index. htm [Accessed 21 October 2010].
26. The use of 'specials' in primary care. DTB 2010; 48: 110-2.
27. Morch K et al. Severe malaria and artesunate treatment, Norway. Emerg Infect Dis 2008; 14: 1816-8.
28. Hien TT et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83.
29. van Hensbroek MB et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335: 69-75.
30. The Artemether-Quinine Meta-analysis Study Group. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg 2001; 95: 637-50.
31. Hien TT et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother 2004; 48: 4234-9. (Pubitemid 39434880)
32. Nealon C et al. Intramuscular bioavailability and clinical efficacy of artesunate in Gabonese children with severe malaria. Antimicrob Agents Chemother 2002; 46: 3933-9. (Pubitemid 35403271)
33. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366: 717-25.
34. Jones KL et al. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2007, Issue 4. Art. No.: CD005967. DOI: 10.1002/14651858.CD005967.pub2 [Last assessed as up-to-date 25 January 2007].
35. Maude RJ et al. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? Am J Trop Med Hyg 2009; 80: 126-32.
36. Jelinek T. Intravenous artesunate recommended for patients with severe malaria: position statement from TropNetEurop. Euro Surveill 2005; 10: E051124.5.